VTGN

2.62

2.96% -0.08

After Hours: 2.60 -0.02 -0.76%

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $2.62, with a volume of 268.90K. It is down -2.96% in the last 24 hours and down -18.63% over the past month.

Previous Close:

$2.70

Open:

$2.71

24h Volume:

268.90K

Relative Volume:

1.41

Market Cap:

$72.95M

Revenue:

$1.04M

Net Income/Loss:

$-32.07M

P/E Ratio:

-0.4063

EPS:

-6.4491

Net Cash Flow:

$-26.12M

1W Performance:

-2.60%

1M Performance:

-18.63%

6M Performance:

-33.50%

1Y Performance:

-36.87%

1-Day Range:

$2.59

$2.75

1-Week Range:

$2.59

$2.90

52-Week Range:

$2.48

$5.86

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1194)

Industry

Biotechnology (682)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2024-11-07

Latest SEC Filings

VTGN's Discussions on Twitter

Compare VTGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTGN Vistagen Therapeutics Inc	2.62	72.95M	1.04M	-32.07M	-26.12M	-3.5091
VRTX Vertex Pharmaceuticals Inc	463.98	119.49B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	754.26	82.89B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	624.96	37.37B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	254.72	32.85B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.70	27.50B	3.30B	-501.07M	1.03B	-2.1146

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Upgrade	Maxim Group	Hold → Buy
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

Nov 30, 2024

VTGN (Vistagen Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 27, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat

Nov 27, 2024

Nov 26, 2024

Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World

Nov 26, 2024

Nov 22, 2024

VTGN Stock Touches 52-Week Low at $2.51 Amid Market Challenges - Investing.com

Nov 22, 2024

Nov 21, 2024

Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada

Nov 21, 2024

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

Nov 21, 2024

Nov 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World

Nov 17, 2024

Nov 15, 2024

Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online

Nov 14, 2024

Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan

Nov 14, 2024

Vistagen to Present at the Stifel 2024 Healthcare Conference - Business Wire

Nov 14, 2024

Nov 11, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat

Nov 11, 2024

Nov 08, 2024